Begin main content

semaglutide

Last Updated: December 24, 2018
Result type: Reports
Project Number: SR0594-000
Product Line: Common Drug Review

Generic Name: semaglutide

Brand Name: Ozempic

Manufacturer: Novo Nordisk Canada Inc.

Indications: Diabetes mellitus, type 2

Manufacturer Requested Reimbursement Criteria1: For the treatment of adults patients with type 2 diabetes to improve glycemic control, in combination with metformin (second line treatment) and in combination with metformin and sulfonylurea (third line treatment).

Submission Type: New

Project Status: Active

Biosimilar: No

Date Recommendation Issued: May 15, 2019

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedOctober 26, 2018
Patient group input closedDecember 14, 2018
Clarification:

- Patient input submission received from Diabetes Canada and Patient Commando

Patient input summary sent for review to patient input groupsJanuary 07, 2019
Patient group comments on input summary closedJanuary 14, 2019
Clarification:

- Patient input summary feedback received

Submission receivedNovember 23, 2018
Submission accepted for reviewDecember 07, 2018
Review initiatedDecember 10, 2018
Draft CADTH review report(s) sent to applicantMarch 05, 2019
Comments from applicant on draft CADTH review report(s) receivedMarch 14, 2019
Redaction requests from applicant on draft CADTH review report(s) receivedMarch 21, 2019
CADTH review team's comments on draft CADTH review report(s) sent to applicantMarch 29, 2019
Canadian Drug Expert Committee (CDEC) meetingApril 10, 2019
CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plansApril 24, 2019
Embargo period ended and validation of redacted CADTH review report(s) receivedMay 08, 2019
CDEC Final Recommendation issued to applicant and drug plansMay 15, 2019
CDEC Final Recommendation postedMay 17, 2019
Final CADTH review report(s) posted-